Left ventricular hypertrophy detection and body mass index in essential hypertension

Blood Pressure

Volumn 19, Issue 6, 2010, Pages 337-343

  Cuspidi, Cesare ^a,b   Giudici, Valentina ^b   Lonati, Laura ^b   Sala, Carla ^c   Valerio, Cristiana ^b   Mancia, Giuseppe ^a,b,c  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Body size; Indexation methods; Left ventricular hypertrophy

Indexed keywords

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY SIZE; BODY SURFACE; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; IMPEDANCE; LEAN BODY WEIGHT; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

BODY HEIGHT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; ITALY; MALE; MIDDLE AGED; PREVALENCE;

EID: 78649265086     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.506029     Document Type: Article

References (27)

1. Bombelli M, Facchetti R, Carugo S, Madotto M, Arenare F, Quarti-Trevano F, et al. Left ventricular hypertrophy increases cardiovascular risk independently of inand out-of office blood pressure values. J Hypertens. 2009;27:2458-2464.
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
3. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Am Intern Med. 1992;117:831-836.
4. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140:848-856.
5. Tsioufis C, Vezali E, Tsiachris D, Dimitriadis K, Taxiarchou E, Chatzis D, et al. Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: A Greek 6-year-follow-up study. J Hypertens. 2009;27:744-752.
6. Cuspidi C. Cardio-renal organ damage and cardiovascular outcomes in hypertension. J Hypertens. 2009;27:702-706.
7. Silbeberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286-290.
8. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004;110:1456-1462.
9. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: A metaanalysis of randomized comparative studies. Hypertension. 2009;54:1084-1091.
10. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens. 2008;21:464-470.
11. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone, Devereux RB, Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension. A meta-analysis. Am J Hypertens. 2003;16:895-899.
12. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. J Am Med Assoc. 2003;289:2560-2572.
13. -2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
14. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
15. Schillaci G, de Simone G, Reboldi G, Porcellati C, Devereux RB, Verdecchia P. Change in cardiovascular risk profile by echocardiography in low-or medium-risk hypertension. J Hypertens. 2002;20:1519-1525.
16. Gottdiener JS, Bednarz J, Devereux RB, Gardin J, Klein A, Manning WJ, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. A report from the American Society of Echocardiography's guidelines and standards committee and the task force on echocardiography in clinical trials. J Am Soc Echocardiogr. 2004;17:1086-1119.
17. de Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. For the Strong Heart Study Investigators. Normalization for body size and population attributable risk of left ventricular hypertrophy. Am J Hypertens. 2005;18:191-196.
18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echo cardiography. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
19. 2.7. J Hypertens. 2009;27:2465-2471.
20. Devereux RB, Reickek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55:613-618.
21. Cuspidi C, Lonati L, Macca G, Sampieri L, Fusi V, Michev I, et al. Prevalence of left ventricular hypertrophy and carotid thickening in a large selected population: Impact of different echocardiographic and ultrasonographic diagnostic criteria. Blood Press. 2001;10:142-149.
22. Dewey FE, Rosenthal D, Murphy DJ, Froelicher VF, Ashley EA. Does size matter? Clinical applications of scaling cardiac size and function for body size. Circulation. 2008;117; 2279-2287.
23. de Simone G, Wacthell K, Palmieri V, Hille DA, Beevers G, Dahlof B, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy. Circulation. 2005;111:1924-1931.
24. Wacthell K, Bella JN, Liebson PR, Gerdts E, Dahlof B, Aalto T, et al. Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population. The LIFE Study. Hypertension. 2000;35:6-12.
25. Ferrara LA, Vaccaro O, Cardoni O, Laurenzi M, Mancini M, Zanchetti A. Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens. 2005;18:1282-1287.
26. Cuspidi C, Meani S, Negri F, Giudici V, Valerio C, Sala C, et al. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: Is the difference limited to obese hypertensives? J Hum Hypertens. 2009;23:728-734.
27. Hans-Werner H, Gneiting B, Muscholl M, Broeckel U, Kuch B, Doering A, et al. The associations of body size and body compositions with left ventricular mass: Impacts for indexation in adults. J Am Coll Cardiol. 1998;32:451-457.